Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 20/20 | 0.87 |
| ▸ | CTSS | P25774 | 11/20 | 0.87 |
| ▸ | CTSL | P07711 | 9/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16485886 | 0.93 | CTSK (1.00) | CTSKCTSSCTSL | |
| SCHEMBL11925963 | 0.93 | CTSK (1.00) | CTSKCTSSCTSL | |
| SCHEMBL21137232 | 0.93 | CTSK (1.00) | CTSKCTSSCTSL | |
| SCHEMBL1146979 | 0.93 | CTSK (1.00) | CTSKCTSSCTSL | |
| SCHEMBL15241284 | 0.93 | CTSK (1.00) | CTSKCTSSCTSL | |
| SCHEMBL1147076 | 0.92 | CTSK (0.73) | CTSKCTSSCTSL | |
| SCHEMBL13450285 | 0.90 | CTSK (0.72) | CTSKCTSSCTSL | |
| SCHEMBL1169381 | 0.90 | CTSK (0.70) | CTSKCTSSCTSL | |
| SCHEMBL13449938 | 0.90 | CTSK (0.72) | CTSKCTSSCTSL | |
| SCHEMBL3167097 | 0.90 | CTSK (0.72) | CTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378209-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2025-08-05 | — | — | US | disclosed |
| US-20220332690-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2022-10-20 | — | — | US | disclosed |
| US-11312693-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2022-04-26 | — | — | US | disclosed |
| US-20210017140-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2021-01-21 | — | — | US | disclosed |
| US-10723709-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2020-07-28 | — | — | US | disclosed |
| US-10329266-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2019-06-25 | — | — | US | disclosed |
| US-20180327371-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2018-11-15 | — | — | US | disclosed |
| US-20170334867-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-11-23 | — | — | US | disclosed |
| US-9428517-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2016-08-30 | — | — | US | disclosed |
| US-20160068539-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2016-03-10 | — | — | US | disclosed |
| US-20140221654-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2014-08-07 | — | — | US | disclosed |
| US-8735395-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2014-05-27 | — | — | US | disclosed |
| US-20130231349-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2013-09-05 | — | — | US | disclosed |
| EP-2331548-B1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2013-09-04 | — | — | EP | disclosed |
| US-8426421-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2013-04-23 | — | — | US | disclosed |
| US-20120289519-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-8242119-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2012-08-14 | — | — | US | disclosed |
| EP-2331548-A1 | PROTEASE INHIBITORS | Medivir AB (SE) | 2011-06-15 | — | — | EP | disclosed |
| US-20110039862-A1 | Protease Inhibitors | MEDIVIR AB (SE) | 2011-02-17 | — | — | US | disclosed |
| WO-2010034788-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289519-A1 | PROTEASE INHIBITORS | F2RL1, F2RL3, PREP | CTSK 67/4885CTSS 36/4885CTSL 7/4885 |
| US-10723709-B2 | Protease inhibitors | CTSK, CTSF, CTSS | CTSK 1/4885CTSS 3/4885CTSL 8/4885 |
| US-11312693-B2 | Protease inhibitors | CTSK, CTSF, CTSS | CTSK 1/4885CTSS 3/4885CTSL 8/4885 |
| US-20160068539-A1 | PROTEASE INHIBITORS | CTSK, CTSF, CTSS | CTSK 1/4885CTSS 3/4885CTSL 8/4885 |
| US-10329266-B2 | Protease inhibitors | CTSK, CTSF, CTSS | CTSK 1/4885CTSS 3/4885CTSL 8/4885 |
| US-12378209-B2 | Protease inhibitors | MMP26, CTSK, TMPRSS6 | CTSK 2/4885CTSS 6/4885CTSL 12/4885 |
| US-20170334867-A1 | PROTEASE INHIBITORS | CTSK, MMP26, MMP3 | CTSK 1/4885CTSS 7/4885CTSL 13/4885 |
| US-20210017140-A1 | PROTEASE INHIBITORS | CTSK, CTSF, CTSS | CTSK 1/4885CTSS 3/4885CTSL 8/4885 |
| US-20110039862-A1 | Protease Inhibitors | CTSK, CTSF, CTSS | CTSK 1/4885CTSS 3/4885CTSL 8/4885 |
| US-20180327371-A1 | PROTEASE INHIBITORS | CTSK, CTSF, CTSS | CTSK 1/4885CTSS 3/4885CTSL 8/4885 |
| US-20130231349-A1 | PROTEASE INHIBITORS | CTSK, CTSF, CTSS | CTSK 1/4885CTSS 3/4885CTSL 8/4885 |
| US-20140221654-A1 | PROTEASE INHIBITORS | CTSK, CTSF, CTSS | CTSK 1/4885CTSS 3/4885CTSL 8/4885 |
| US-20220332690-A1 | PROTEASE INHIBITORS | MMP26, CTSK, TMPRSS6 | CTSK 2/4885CTSS 6/4885CTSL 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.